Year-end Report, January – December 2016
Completed listing prepares Acarix for commercialization of CADScor®System
"Heart disease is the number one killer worldwide and Coronary Artery Disease (CAD) affects more than 120 million people annually causing 1 in 6 deaths globally. However, 90% of patients seeking medical care are not suffering from CAD, which means healthy patients are undergoing invasive and potentially harmful diagnostic tests and spiraling healthcare costs. At Acarix, we are determined to help healthcare providers and policy makers deliver better patient selection and more efficient diagnostic pathways, and the Acarix CADScor®System offers exactly that opportunity to benefit both individual patients and society at large."
Extract from CEO SØREN RYSHOLT CHRISTIANSENs commentary to the Year-end Report.
Fourth quarter (October – December) in 2016 compared with same period 2015
- Operating loss amounted to kSEK -15,043 (-2,256)
- Net loss amounted to kSEK -14,944 (-1,522)
- Net increase in cash and cash equivalents amounted to kSEK 143,970 (-1,613) supported by capital increase amounting to kSEK 176,698 (-31)
- Earnings per share before and after dilution (weighted average) amounted to SEK -0.87 (-0.13)
- Completed IPO of new shares and listing on Nasdaq First North Premier Stockholm, raising MSEK 140 in equity before transaction costs
- The board proposes to the AGM that no dividend is paid
Financial year 2016compared with financial year 2015
- The company has not yet engaged in any sales activities and had no revenue during the year
- Operating loss amounted to kSEK -26,790 (-15,377)
- Net loss amounted to kSEK -48,240 (-12,393)
- Net increase in cash and cash equivalents amounted to kSEK 143,774 (-6,565)
- Cash and cash equivalents amounted to kSEK 145,895 (2,121)
- Earnings per share before and after dilution (weighted average) amounted to SEK -3.68 (-1.14). Acarix have no outstanding warrants
Events occurring after December 31, 2016
Acarix and the CADScor®System was presented at Medtech Showcase in San Francisco. This provided an immediate opportunity to capitalize on the interest generated by the initial public offering, and meet potential US and international collaborators.
The complete year-end report is available by link below or on www.acarix.com
For further information, please contact:
Søren Rysholt Christiansen, CEO, +45 2777 1112, dksrc@acarix.com
Christian Lindholm, CFO, +46 705 118 333, secli@acarix.com
The information disclosed in this year-end report is mandatory for Acarix AB (publ) to publish pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. This information was submitted through the agency of the CEO. PR_Acarix_Q4_2016 eng_Final
Acarix Q4 2016_ENG
—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire
